Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

September launch of Ambrotose A.O. antioxidant supplement helps boost revenues 44.1% to $49.7 mil. for the third quarter ended Sept. 30 versus the prior-year period, Coppell, Texas-based direct marketer reports Nov. 7. CEO Sam Caster believes the product could total 25% of Mannatech's gross sales by 2005 (1"The Tan Sheet" Aug. 25, 2003, p. 15). Mannatech's net income rose to $2.9 mil. compared with $200,000 in the year-ago period...

You may also be interested in...

Mannatech results

Dietary supplement direct seller reports consolidated net sales increase of 35.6% to $191 mil. in 2003, as income more than tripled over the prior year to $8.8 mil. Coppell, Texas-based company recorded sales of $54.3 mil. in the fourth quarter, up 9.2% over same period in 2002. Mannatech attributes improved annual performance in part to antioxidant product Ambrotose AO, launched last September (1"The Tan Sheet" Nov. 17, 2003, In Brief). Firm plans launches in South Korea in second half of 2004 and Taiwan in first quarter 2005...

Mannatech Posts Solid Q2; Launching Antioxidant, Intestinal Products

Mannatech's new antioxidant supplement, Ambrotose A.O., could represent 25% of the company's gross sales worldwide by 2005, according to company CEO Sam Caster

FDA Talks Tough On Complete Response Extensions

The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts